Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001333746 | SCV001526420 | uncertain significance | Atypical glycine encephalopathy | 2018-03-01 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Labcorp Genetics |
RCV001333746 | SCV002306209 | uncertain significance | Atypical glycine encephalopathy | 2024-02-24 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 209 of the SLC6A9 protein (p.Ser209Leu). This variant is present in population databases (rs201065535, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with SLC6A9-related conditions. ClinVar contains an entry for this variant (Variation ID: 1031820). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004968047 | SCV005510338 | uncertain significance | Inborn genetic diseases | 2024-11-24 | criteria provided, single submitter | clinical testing | The c.626C>T (p.S209L) alteration is located in exon 5 (coding exon 5) of the SLC6A9 gene. This alteration results from a C to T substitution at nucleotide position 626, causing the serine (S) at amino acid position 209 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |